Companies · Biotechnology

Koios Medical, Inc.

NEW YORK · Biotechnology

Diligence memoA one-page analyst read on Koios Medical, Inc. — recommendation, valuation, rhythm, risks.
$16.0M
Total raised · real
5
Rounds
764.7×
Latest step-up
Top 36%
Sector rank · raised
Series A
Latest stage · inferred · Fri May 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Koios Medical, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Koios Medical, Inc. is one of 4293 Biotechnology companies tracked from NEW YORK. By capital raised it ranks mid-pack (ahead of 65% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2024-05-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2018-12-28 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2018Series A · 2021-01-26 Raised $280K (real) Modeled valuation $7.7M (est)$280K$7.7MSeries A2021Series A · 2021-11-16 Raised $2.6M (real) Modeled valuation $48M (est)$2.6M$48MSeries A2021Series A · 2023-02-03 Raised $8.0M (real) Modeled valuation $83M (est)$8.0M$83MSeries A2023Series A · 2024-05-17 Raised $170K (real) Modeled valuation $948K (est)$170K$948KSeries A2024Series D+ · 2024-05-17 Raised $130M (real) Modeled valuation $1.5B (est)$130M$1.5BSeries D+2024+$280K+$2.6M+$8.0M+$170K+$130MCumulative $146M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2018
Series A extension$280K · 2021
Series A extension$2.6M · 2021
Series A extension$8.0M · 2023
Series A extension$170K · 2024
Series D+$130.0M · 2024no Series B / Series C on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$948K
Base estimate est.
$185K
Conservative case
$2.1M
Upside case
$773K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2018-12-282018Series A · modeled $7.7M · 2021-01-26Series A · modeled $48.4M · 2021-11-16Series A · modeled $82.8M · 2023-02-03Series A · modeled $948K · 2024-05-17Series D+ · modeled $1.5B · 2024-05-172024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.1 yr
Elapsed time used
2.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$3.0M/yr
Capital velocity
7.5 yr
On record since
2018
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.2× above median
This company$16.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 24× above median
This company$130.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$948K
Sector median$64.2M

Raised more than 65% of sector peers (real $). Modeled value above 3% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #302 of 303.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Koios Medical, Inc. (this company) Raised $16.0M · modeled $948K (est)Koios Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Koios Medical, Inc. this companySeries A$16.0M$948K0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2018-12-28$22.7M$180.8M90%
Series A$280K2021-01-26$1.3M$7.7M90%
Series A$2.6M2021-11-16$11.8M$48.4M90%
Series A$8.0M2023-02-03$36.4M$82.8M90%
Series A$170K2024-05-17$773K$948K90%
Series D+$130.0M2024-05-17$1.1B$1.5B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2018-12-28
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series A$280K2021-01-26
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 17.9× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  3. Series A$2.6M2021-11-16
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 9.3× larger than the prior — scaling up.
    • 25 investors on this round.
  4. Series A$8.0M2023-02-03
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 3.1× larger than the prior — scaling up.
    • 1 investor on this round.
  5. Series A$170K2024-05-17
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 47.1× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  6. Series D+$130.0M2024-05-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 764.7× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~13mo cadence
$390.0M
Modeled next size est.range $253.5M$624.0M
764.7×
Last step-up
$3.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Graham Anderson4 other2021-11
Christine Chad Li2024-05
Christine Li Shuling2023-02
Gregory Chad Moran2024-05
Gregory E. Moran2021-11
Gregory Li Moran2023-02
John Li Walker2023-02
Mark Chad Glasgold2024-05
Mark E. Glasgold2021-11
Mark Li Glasgold2023-02
Robert Chad McClennan2018-12
Robert Li McClennan2023-02
William E. Peterson2021-11
Registry & provenance

Koios Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1764417
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Ordaos, Inc.BiotechnologySeries A$16.8M$1.3Msame sector · same stage
Bioscience Americas, LLCBiotechnologySeries A$15.1M$4.3Msame sector · same stage
SenesTech, Inc.BiotechnologySeries A$17.2M$848Ksame sector · same stage
Calviri IncBiotechnologySeries A$17.4M$3.5Msame sector · same stage
Adaptin Bio, Inc.BiotechnologySeries A$14.7M$4.3Msame sector · same stage
StemoniX, Inc.BiotechnologySeries A$14.6M$3.6Msame sector · same stage
Gregor Diagnostics, Inc.BiotechnologySeries A$14.5M$678Ksame sector · same stage
Luminary Therapeutics, Inc.BiotechnologySeries A$14.5M$4.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Koyo Sciences Inc.BiotechnologySeed$3.7M90%
Korro Bio, Inc.BiotechnologySeed$177.6M89%
Kolon TissueGene, Inc.BiotechnologySeries B$261.4M89%
Akouos, Inc.BiotechnologySeries D+$4.3B89%
Kronos Bio, Inc.BiotechnologySeries D+$4.3B89%
Capio Biosciences, Inc.BiotechnologySeed$128.8M87%
Akonni Biosystems IncBiotechnologySeries A$64.2M87%
Ekso Bionics Holdings, Inc.BiotechnologySeries C$113.4M87%
Frequently asked
How much funding has Koios Medical, Inc. raised?
Koios Medical, Inc. has raised approximately $16.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Koios Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Koios Medical, Inc. is approximately $948K (modeled range $185K–$2.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Koios Medical, Inc. at?
Koios Medical, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri May 17.
What does Koios Medical, Inc. do and where is it based?
Koios Medical, Inc. operates in the Biotechnology sector, based in NEW YORK.
Explore related

See where Koios Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Koios Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.